Related Experiment Video
Updated: Aug 21, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Rosuvastatin in the management of hyperlipidemia
1Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, New York, USA. judy.cheng@liu.edu
Insights
Rosuvastatin effectively lowers LDL cholesterol and raises HDL cholesterol, offering potent lipid-lowering effects. This statin demonstrates high efficacy and tolerability, potentially helping patients reach cholesterol goals with lower doses.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism Disorders
Background:
- Rosuvastatin is a statin used to manage hypercholesterolemia, mixed dyslipidemia, and familial hypercholesterolemia.
- It aims to reduce total cholesterol, LDL-C, and triglycerides while increasing HDL-C.
Purpose of the Study:
- To review the pharmacology, clinical efficacy, and tolerability of rosuvastatin.
- Evaluation included its use in monotherapy and combination therapy for hyperlipidemia.
Main Methods:
- A literature review was performed using the search term 'rosuvastatin'.
- Searched databases included MEDLINE and Current Contents (1966–March 2004).
- English-language peer-reviewed articles and abstracts were analyzed.
Main Results:
- Rosuvastatin (10–40 mg/d) reduced LDL-C by 43–63% and increased HDL-C by approximately 10%.
- It exhibited higher potency in lowering LDL-C compared to other statins like atorvastatin and simvastatin.
- Rosuvastatin was well-tolerated with rare myopathy and liver function abnormalities, and fewer drug interactions due to non-CYP450 metabolism.
Conclusions:
- Achieving optimal LDL-C levels is crucial for reducing cardiovascular events.
- Rosuvastatin may help patients reach target LDL-C goals sooner with lower doses.
- This could decrease the need for dose titration or combination therapy.
Background:
Rosuvastatin is a new statin indicated to reduce elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides and to increase levels of high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia.
Objective:
The purpose of this article was to review the pharmacology, clinical efficacy, and tolerability of rosuvastatin as monotherapy and combination therapy for patients with hyperlipidemia.
Methods:
A literature review was conducted using the search term rosuvastatin to identify English-language peer-reviewed articles and abstracts in the MEDLINE and Current Contents databases (both 1966 to March 2004). Citations from available articles were reviewed for additional references, and selected information from the manufacturer was discussed.
Results:
Rosuvastatin 10 to 40 mg/d reduced LDL-C by 43% to 63% (P < 0.05). Compared with other statins, rosuvastatin had the highest dose-to-dose potency in lowering LDL-C (reduction of 60% vs 50% with atorvastatin, 40% with simvastatin, 30% with pravastatin or lovastatin, and 20% with fluvastatin) and better efficacy in raising HDL-C (increase of approximately 10% vs approximately 5% with other statins; P < 0.05). Rosuvastatin enabled significantly more patients to achieve the National Cholesterol Education Program (NCEP) goals for LDL-C with lower doses (P < 0.05). Rosuvastatin was well tolerated. Incidences of myopathy and liver function test abnormalities were rare and comparable to those of other statins. Because it is not metabolized by the cytochrome P-450 enzymes, rosuvastatin had fewer clinically significant drug interactions compared with other statins. Studies to assess the effect of rosuvastatin on cardiovascular outcomes are ongoing.
Conclusions:
Clinical studies continue to demonstrate that achieving optimal levels of LDL-C is an important goal in reducing cardiovascular events. Recent evidence suggests the need for an even lower LDL-C goal than that being recommended by the NCEP Based on the studies included in this review, rosuvastatin may help patients achieve optimal goals early with lower dosages, thus reducing the need for dose titration or combination therapy.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:26Angina IV: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:23Atherosclerosis IV: Nursing Management
01:27Coronary Artery Disease V: Interprofessional Care